Dana-Farber Cancer Institute
450 Brookline AvenueBoston, MA 02215
Dr. Shulman studies novel therapies and biomarkers for patients with advanced sarcomas. In addition to early phase clinical trials, Dr. Shulman co-leads an effort to evaluate circulating tumor DNA, a type of "liquid biopsy," as a potential tool to improve the ways in which we treat patients with bone and soft tissue sarcomas.
| University | Degree | Focus | Graduated |
|---|---|---|---|
| Harvard Medical School | Doctorate | Other | 2013 |
| Institution | Focus | Year |
|---|---|---|
| Residency - Boston Combined Residency Program, Boston Children's Hospital/ Boston Medical Center, Pediatrics | Other | Not Specified |
| Fellowship - Dana-Farber Cancer Institute and Boston Children's Hospital | Other | Not Specified |
Accepts New Patients: Yes
David Shulman, MD has not yet listed the medications that he commonly prescribes.
David Shulman, MD has not yet specified the insurance plans he accepts.